Aurinia Pharmaceuticals v. Dr. Reddy’s: LUPKYNIS Voclosporin Patent Dispute
Aurinia Pharmaceuticals filed suit in the District of New Jersey against Dr. Reddy’s Laboratories over two patents covering its LUPKYNIS (voclosporin) drug product — a calcineurin inhibitor approved for lupus nephritis. The case was consolidated for all pre-trial purposes within 216 days of filing, suggesting parallel ANDA-related proceedings are being coordinated.
Voclosporin ANDA Battle: Aurinia Moves to Protect LUPKYNIS Franchise
Aurinia Pharmaceuticals, Inc. filed this patent infringement action on May 1, 2025 in the United States District Court for the District of New Jersey against Dr. Reddy’s Laboratories, Ltd. The suit asserts two patents — US11622991B2 and US10286036B2 — covering the voclosporin compound and formulation underlying Aurinia’s commercially marketed LUPKYNIS product, an FDA-approved calcineurin inhibitor for the treatment of active lupus nephritis in adults.
The case was closed on December 3, 2025, not on the merits but pursuant to a consolidation order. The court ordered this action and related cases consolidated into a single proceeding for all pre-trial purposes, including discovery and case management. Consolidation at this stage is procedurally standard in multi-defendant Hatch-Waxman ANDA litigation, where a branded drug manufacturer sues multiple generic filers in coordinated actions and the court streamlines pre-trial management.
The 216-day period from filing to consolidation order is consistent with the routine early administration of complex pharmaceutical patent cases in New Jersey, a jurisdiction that handles a high volume of Hatch-Waxman matters. The public record does not yet disclose claim construction schedules, invalidity contentions, or settlement discussions. It remains unknown from available records whether additional ANDA filers have been sued, or whether any 30-month stay under Hatch-Waxman is currently in effect protecting LUPKYNIS market exclusivity.
Filing to Case Consolidated in 216 days
216 days to consolidation order — consistent with early-stage ANDA Hatch-Waxman case management timelines
Case consolidated: what the court’s order means for both parties
Consolidation merges parallel actions, not a merits ruling
A consolidation order under Fed. R. Civ. P. 42(a) combines related cases for procedural efficiency — here, for all pre-trial purposes including discovery and case management. It does not resolve any patent validity or infringement question. The underlying claims remain live, and both parties retain all substantive positions. The consolidated action will proceed under unified scheduling before the same judge.
Procedural — no merits decidedAurinia gains coordinated discovery across all generic challengers
Consolidation typically benefits the branded drug plaintiff in multi-defendant ANDA litigation by creating a unified discovery record, reducing duplicative motions, and enabling consistent claim construction positions across all generic filers. Aurinia can present a single, coherent infringement and validity case while potentially leveraging a 30-month Hatch-Waxman stay to maintain market exclusivity during litigation.
Efficient enforcement postureDr. Reddy’s faces coordinated opposition with other generic filers
Consolidation means Dr. Reddy’s will litigate alongside any co-defendants in a shared pre-trial framework, which can reduce individual costs but also limits strategic flexibility. The generic challenger must now advance invalidity and non-infringement arguments in a coordinated proceeding. Entry timing for its generic voclosporin product remains contingent on the outcome of the consolidated patent dispute.
Generic market entry delayedLUPKYNIS exclusivity window tied to litigation trajectory
LUPKYNIS generated significant revenue for Aurinia in the lupus nephritis market. The consolidation of ANDA challenges signals that multiple generic manufacturers are pursuing entry, heightening competitive pressure. Until the consolidated action resolves on the merits or through settlement, the branded voclosporin franchise benefits from litigation-driven market protection. The outcome will set a precedent for calcineurin inhibitor formulation patents.
Branded exclusivity at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Aurinia Pharmaceuticals, Inc. | Company | Biopharmaceutical company — holder of US11622991B2 and US10286036B2 covering LUPKYNIS (voclosporin)Search in Eureka ↗ |
| Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Global generic pharmaceutical manufacturer; ANDA filer seeking to market generic voclosporinSearch in Eureka ↗ |
| Plaintiff counsel | C. COLLETTE CORSER | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | DANIELLE A. DUSZCZYSZYN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EMILY R. GABRANSKI | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JUSTIN SILVERBERG | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | MARK FELDSTEIN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | RYAN V. MCDONNELL | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Deni , Jr. | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order consolidates the captioned actions for all pre-trial purposes including discovery and case management, expressly subject to further court order. The phrasing ‘subject to further order’ preserves judicial flexibility to de-consolidate or modify the arrangement as the case develops. Critically, the order does not adjudicate infringement, validity, or enforceability of either asserted patent — both parties’ substantive positions remain entirely open. The consolidation record suggests at least one parallel action exists, consistent with a multi-defendant ANDA filing scenario.
US11622991B2 & US10286036B2 — Voclosporin formulation and treatment patents
US11622991B2 (application no. US17/713140) and US10286036B2 (application no. US15/835219) together protect voclosporin — a novel calcineurin inhibitor and the active ingredient in LUPKYNIS, the first FDA-approved calcineurin inhibitor specifically indicated for active lupus nephritis in adults. The patents cover aspects of the voclosporin compound, its pharmaceutical formulations, and therapeutic use methods. US10286036B2’s earlier application date suggests it covers foundational formulation claims, while US11622991B2 likely captures subsequent refinements or dosing innovations.
For the lupus nephritis market, these patents represent a significant commercial barrier to generic entry. LUPKYNIS is a differentiated product in an underserved autoimmune indication with substantial patient need and pricing power. Any generic challenger must either design around both patents or invalidate them — a high bar given their layered claim scope. Competitors in the calcineurin inhibitor and immunosuppressant drug space, as well as biosimilar developers targeting lupus nephritis, should monitor claim construction rulings in this consolidated action closely.
Should you run an FTO against US11622991B2 and US10286036B2?
Any company developing generic, biosimilar, or novel formulations of voclosporin or related calcineurin inhibitors for autoimmune indications — particularly lupus nephritis — should treat these two patents as primary FTO targets. The consolidated litigation signals that Aurinia is actively enforcing its IP estate against ANDA filers. R&D teams working on immunosuppressant drug delivery, calcineurin inhibitor analogues, or combination therapies for lupus nephritis should assess claim scope before advancing to IND or NDA/ANDA filing.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US11622991B2 and US10286036B2, identify prior art bearing on validity, and surface related prosecution history that may define claim boundaries. Eureka’s litigation monitoring layer will alert your team to new claim construction orders, scheduling milestones, or settlements in the consolidated NJ action — enabling real-time adjustment of your freedom-to-operate and competitive intelligence strategy.
Run a freedom-to-operate analysis on US11622991B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA patent cases in the District of New Jersey
Explore related calcineurin inhibitor and immunosuppressant drug patent infringement cases filed in the District of New Jersey under the Hatch-Waxman framework.
What this case signals for the pharmaceutical patent IP landscape
This Hatch-Waxman consolidation in New Jersey is an early marker in what could become a sustained multi-front defence of the voclosporin franchise.
New Jersey remains the preferred venue for ANDA patent consolidations
The District of New Jersey consistently handles among the highest volumes of Hatch-Waxman patent cases in the US. Aurinia’s choice of venue and the court’s swift consolidation order reflect an established local practice for managing multi-defendant pharmaceutical patent litigation efficiently. IP teams monitoring branded drug defence strategies should track NJ District Court scheduling orders in this consolidated action.
Two asserted patents create layered invalidity risk for generic challengers
Asserting both US11622991B2 and US10286036B2 gives Aurinia redundancy — a generic challenger must successfully invalidate or design around both patents to achieve freedom to operate. This layered assertion strategy is common in calcineurin inhibitor and immunosuppressant drug litigation and raises the cost and complexity of ANDA-related paragraph IV challenges.
Aurinia v Dr. — key questions answered
Aurinia asserted two patents: US11622991B2 (application no. US17/713140) and US10286036B2 (application no. US15/835219). Both cover aspects of voclosporin — the active ingredient in LUPKYNIS — including its pharmaceutical formulations and methods of treatment for lupus nephritis.
The court ordered the captioned actions consolidated for all pre-trial purposes, including discovery and case management. This is a procedural step — it does not resolve infringement or validity. Consolidation is common in multi-defendant Hatch-Waxman ANDA litigation to streamline parallel proceedings before the same court.
The public record available for case 2:25-cv-03693 does not confirm whether a 30-month stay under the Hatch-Waxman Act is currently operative. However, the filing of a timely patent infringement action within 45 days of receiving an ANDA paragraph IV notice typically triggers an automatic 30-month stay of FDA final approval. Practitioners should review the ANDA filing timeline to assess stay status.
Voclosporin is a novel calcineurin inhibitor and the active ingredient in LUPKYNIS (voclosporin), the first FDA-approved calcineurin inhibitor specifically for active lupus nephritis in adults. It represents a significant commercial asset for Aurinia in a historically underserved autoimmune indication, making its patent estate a high-value enforcement target against generic challengers.
Aurinia Pharmaceuticals is represented by Gibbons PC, with attorneys including William P. Deni Jr., J. Brugh Lower, Mark Feldstein, and others. Dr. Reddy’s Laboratories is represented by Midlige Richter LLC, with James S. Richter listed as defendant’s counsel of record in the District of New Jersey proceedings.
PatSnap Eureka searches patents and litigation data to answer instantly.